Is EXACT Sciences Corporation (EXAS) overvalued? · rev $2.76B
EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ.
This page asks whether EXACT Sciences Corporation (EXAS) looks expensive on cached numbers — not a short thesis.
Latest reported EXAS revenue for 2024-12-31 was $2.76B. Net income was -$1.03B. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. EXAS currently screens at market cap $20.03B.
EXAS currently screens at market cap $20.03B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next EXAS 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the EXAS stock page for the full model, not this heading.
Not investment advice.